Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health venture funding hit $7.4 billion in the first half of 2026, with deals of $100 million or more driving the bulk of that volume, according to Modern Healthcare citing Rock Health data. The figure arrives alongside a cluster of structural moves that signal the sector has crossed from experimentation into operational deployment: the Centers for Medicare and Medicaid Services has created a dedicated health technology office, Tempus AI has agreed to acquire cancer genomics company Personalis for $1.7 billion, and AI-powered revenue cycle management is attracting nine-figure rounds as hospital staffing pressures intensify.

CMS institutionalizes health technology with a new office

In June 2026, CMS established the Office of Health Technology and Products, a move reported by Healthcare Dive's Emily Olsen. The office consolidates the agency's health tech strategy under one roof, with a mandate covering digital health tool design, AI implementation management, and healthcare data exchange.

Amy Gleason, who has served as a strategic advisor to CMS under the Trump administration and leads the agency's Health Tech Ecosystem initiative, was named deputy administrator and chief product officer for the new office, according to Healthcare Dive. The Health Tech Ecosystem is focused on expanding data sharing and accelerating digital health adoption across Medicare and Medicaid.

For health system operators and technology vendors, the creation of a single office with a named executive accountable for AI and interoperability at CMS changes the procurement calculus. Programs that previously sat across scattered CMS divisions now have a single regulatory and product counterpart. Compliance and integration requirements are likely to sharpen as the office matures.

Tempus AI's $1.7B Personalis bet raises the stakes in cancer genomics

Tempus AI announced a $1.7 billion agreement to acquire Personalis, a cancer genomics technology firm, with the deal expected to close in late 2026 or early 2027, according to Modern Healthcare. The acquisition extends Tempus AI's reach deeper into molecular data, a resource that underpins both clinical decision support and pharmaceutical partnerships.

The deal is one of the largest AI-driven health tech acquisitions announced this year and reflects a broader pattern Modern Healthcare has tracked: buyers that made acquisitions in 2025 are now translating those deals into new partnerships and expanded service lines in 2026. Enterprise health system leaders evaluating precision oncology infrastructure should expect the combined Tempus-Personalis platform to compete for multi-year agreements that integrate genomic sequencing data with clinical AI workflows.

RCM staffing shortfalls accelerate AI vendor adoption

Hospital revenue cycle departments are under measurable strain. Staffing shortages combined with rising documentation complexity are pushing health systems to evaluate outside AI vendors for billing, prior authorization, and coding workflows, Modern Healthcare reported. Companies including Akasa are competing for those contracts as hospitals seek automation that can absorb volume that human teams cannot.

The demand signal is also drawing new capital. Candid Health, an AI-powered RCM automation company founded in 2019, closed a $120 million Series D round, a deal that tripled the company's valuation compared with its 2025 fundraise, according to Fierce Healthcare. Separately, Assured, an AI-native provider credentialing and enrollment startup, raised a $19 million Series A, Fierce Healthcare reported, adding further evidence that AI vendors targeting administrative workflows are attracting investor conviction alongside hospital interest.

Modern Healthcare's AI tracker also noted that Bunkerhill Health, a clinical AI company, reached $55 million in total funding in July 2026. That milestone, modest relative to the sector's mega deals, reflects how capital is distributing across clinical, administrative, and genomic AI categories simultaneously rather than concentrating in a single application.

Clinical AI still has a trust problem operators need to solve

Not every signal is straightforwardly bullish. Modern Healthcare reported that Aidoc CEO and co-founder Elad Walach views provider trust as the central obstacle to growth for clinical AI companies. Aidoc has secured funding and a growing customer base, but the framing is important for CIOs and CMIOs evaluating vendor claims: even well-capitalized clinical AI platforms face resistance when clinicians cannot interpret or verify model recommendations.

Google's chief health officer, Dr. Michael Howell, told Modern Healthcare that the company sees early promise for AI in virtual care and medical record review, and is focused on building an evidence base to support broader deployment. The explicit emphasis on evidence rather than capability signals that even the largest technology companies recognize that clinical trust requires published outcomes data, not just product demonstrations.

For procurement leaders, the practical implication is clear: vendor selection in clinical AI should include evidence requirements and pilot outcome commitments as contract terms, not just post-sale aspirations. The first half of 2026 has produced more capital, more deals, and more regulatory infrastructure around health technology than any comparable period. The next competitive advantage belongs to the operators who know how to evaluate what they are buying.

What this means for your team

• Reassess RCM vendor options against the current funding landscape: Candid Health's 3x valuation increase and Akasa's hospital traction signal that AI-native RCM vendors now have the capitalization to support enterprise-scale contracts and SLA commitments.
• Map your AI product portfolio against the CMS Office of Health Technology and Products: Amy Gleason's mandate covers AI implementation and interoperability standards, so any vendor you deploy will face tightening CMS expectations on data exchange compliance.
• Require published clinical evidence in any AI vendor RFP: both Aidoc's trust challenge and Google's evidence-building stance confirm that outcome data is the new differentiator. Build evidence requirements and pilot benchmarks into contract terms, not just procurement conversations.
• Track the Tempus AI and Personalis deal close: if oncology or genomics informatics sits in your strategic roadmap, the combined platform will reshape vendor competition in precision oncology workflows before mid-2027.